Stock

Here is where you can buy Cassava Sciences stock (SAVA): it is up 7% today

After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%.

The current bullish outlook is a result of a denial by the FDA against Citizen Petitions Filed on Behalf of Short Selling Clients.

In a statement issued by the President & CEO of Cassava Sciences after the news Remi Barbier, it said:

“The news is very welcome but not surprising… We said from the outset that the allegations are false.”

To help stock traders eying the Cassava Sciences stock (SAVA), Invezz has created a brief article on what it is and the best places to buy it.

To find out more, please continue reading.

Best places to buy Cassava Sciences stock              

eToro

eToro is one of the world’s leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It’s social copy trading features make it a great choice for those getting started.


Register with eToro instantly

Pepperstone

Pepperstone was founded in 2010 in Melbourne, Australia by a team of experienced traders with a shared commitment to improve the world of online trading. Frustrated by delayed executions, expensive prices and poor customer support, they set out to provide traders around the world with superior technology, low-cost spreads and a genuine commitment to helping them master the trade. Their mission is to create a world of tech-enabled trading where ambitious traders can embrace the challenge and opportunity of global markets.


Register with Pepperstone instantly

What is Cassava Sciences stock?

Cassava Sciences stock is the stock of Cassava Sciences, Inc. Company and it trades on NASDAQ under the symbol NASDAQ: SAVA.

Cassava Sciences operates as a clinical-stage biotechnology company that develops drugs for neurodegenerative diseases like Alzheimer’s. Its top therapeutic products include simufilam, a small molecule drug, and SavaDx, a blood-based diagnostic drug for detecting Alzheimer’s disease.

Cassava Sciences was previously known as Pain Therapeutics, Inc.

Should I buy the SAVA stock today?

If you are looking to take advantage of a stock whose price has largely dipped over the recent past but has shown signs of bouncing back, then the SAVA stock could be a good choice.

However, there are still not very strong indicators as to how far the current bullish trend could go and is therefore important to be wary of the fact that the stock could decide to resume the bearing trend.

Cassava Sciences stock price prediction

Based on a forecast from several stock analysts, the SAVA stock is expected to see a long-time price hike towards $60 before the end of February 2022.

$SAVA stock social media coverage

$SAVA

FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients

“The news is very welcome but not surprising,” said Remi Barbier, President & CEO. “We said from the outset that the allegations are false.https://t.co/RaNY59HI4s

— Cassava Sciences – UOF – Investors (@CassavaSciences) February 10, 2022

FDA just rejected the CP against $SAVA 👏👏👏👏🧨🧨🧨🧨

Congrats to all $SAVA longs. A day for party 🎉🎉🎉🎉 https://t.co/VfvIglc2ZF

— Luosheng Peng (@LuoshengPeng) February 10, 2022

The post Here is where you can buy Cassava Sciences stock (SAVA): it is up 7% today appeared first on Invezz.

Disclaimer: MonopolyWinnersUpdates.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 MonopolyWinnersUpdates.com. All Rights Reserved.

To Top